Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: A retrospective study
Open accessAbstract
Background Demyelination of cerebral white matter is thought to drive neuronal degeneration and permanent neurological disability in individuals with multiple sclerosis. Findings from brain MRI studies, however, support the possibility that demyelination and neuronal degeneration can occur independently. We aimed to establish whether post-mortem brains from patients with multiple sclerosis show pathological evidence of cortical neuronal loss that is independent of cerebral white-matter demyelination. Methods Brains and spinal cords were removed at autopsy from patients, who had died with multiple sclerosis, at the Cleveland Clinic in Cleveland, OH, USA. Visual examination of centimetre-thick slices of cerebral hemispheres was done to identify brains without areas of cerebral white-matter discoloration that were indicative of demyelinated lesions (referred to as myelocortical multiple sclerosis) and brains that had cerebral white-matter discolorations or demyelinated lesions (referred to as typical multiple sclerosis). These individuals with myelocortical multiple sclerosis were matched by age, sex, MRI protocol, multiple sclerosis disease subtype, disease duration, and Expanded Disability Status Scale, with individuals with typical multiple sclerosis. Demyelinated lesion area in tissue sections of cerebral white matter, spinal cord, and cerebral cortex from individuals classed as having myelocortical and typical multiple sclerosis were compared using myelin protein immunocytochemistry. Neuronal densities in cortical layers III, V, and VI from five cortical regions not directly connected to spinal cord (cingulate gyrus and inferior frontal cortex, superior temporal cortex, and superior insular cortex and inferior insular cortex) were also compared between the two groups and with aged-matched post-mortem brains from individuals without evidence of neurological disease. Findings Brains and spinal cords were collected from 100 deceased patients between May, 1998, and November, 2012, and this retrospective study was done between Sept 6, 2011, and Feb 2, 2018. 12 individuals were identified as having myelocortical multiple sclerosis and were compared with 12 individuals identified as having typical multiple sclerosis. Demyelinated lesions were detected in spinal cord and cerebral cortex, but not in cerebral white matter, of people with myelocortical multiple sclerosis. Cortical demyelinated lesion area was similar between myelocortical and typical multiple sclerosis (median 4·45% [IQR 2·54-10·81] in myelocortical vs 9·74% [1·35-19·50] in typical multiple sclerosis; p=0·5512). Spinal cord demyelinated area was significantly greater in typical than in myelocortical multiple sclerosis (median 3·81% [IQR 1·72-7·42] in myelocortical vs 13·81% [6·51-29·01] in typical multiple sclerosis; p=0·0083). Despite the lack of cerebral white-matter demyelination in myelocortical multiple sclerosis, mean cortical neuronal densities were significantly decreased compared with control brains (349·8 neurons per mm 2 [SD 51·9] in myelocortical multiple sclerosis vs 419·0 [43·6] in controls in layer III [p=0·0104]; 355·6 [46·5] vs 454·2 [48·3] in layer V [p=0·0006]; 366·6 [50·9] vs 458·3 [48·4] in layer VI [p=0·0049]). By contrast, mean cortical neuronal densities were decreased in typical multiple sclerosis brains compared with those from controls in layer V (392·5 [59·0] vs 454·2 [48·3]; p=0·0182) but not layers III and VI. Interpretation We propose that myelocortical multiple sclerosis is a subtype of multiple sclerosis that is characterised by demyelination of spinal cord and cerebral cortex but not of cerebral white matter. Cortical neuronal loss is not accompanied by cerebral white-matter demyelination and can be an independent pathological event in myelocortical multiple sclerosis. Compared with control brains, cortical neuronal loss was greater in myelocortical multiple sclerosis cortex than in typical multiple sclerosis cortex. The molecular mechanisms of primary neuronal degeneration and axonal pathology in myelocortical multiple sclerosis should be investigated in future studies. Funding US National Institutes of Health and National Multiple Sclerosis Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Demyelination of cortical grey matter is an important characteristic of MS, and in many patients the proportion of demyelinated grey matter outweighs that of demyelinated white matter.
“Demyelination of the cortical grey matter is an important characteristic of MS, and the proportion of demyelinated grey matter outweighs that of demyelinated white matter in many patients.46,47”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [47]
The Introduction describes cortical demyelination as a prominent feature of postmortem MS brains. The Discussion reports cortical demyelination without significant cerebral white-matter demyelination in the myelocortical MS subgroup (12 of 97 autopsy cases). It does not establish that the proportion of demyelinated grey matter exceeds that of white matter in many MS patients generally. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029 · see citing works
Self-citationPeterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 27
- [1]Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247– 69. 18558855
- [3]Bjartmar C, Kidd G, Mörk S, Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893– 901. 11117546
- [4]Filippi M, Rocca MA, Ciccarelli O, MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016; 15: 292– 303. 26822746 PMC4760851
- [5]van Munster CE, Uitdehaag BM. Outcome Measures in Clinical Trials for Multiple Sclerosis. CNSDrugs 2017; 31: 217– 36. PMC5336539 28185158
- [6]Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669– 76. 23743084
- [7]de Groot CJ, Bergers E, Kamphorst W, Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124: 1635– 45. 11459754
- [8]Fisher E, Chang A, Fox RJ, Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007; 62: 219– 28. 17427920
- [9]Rudick RA, Fisher E, Lee JC, Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000; 6: 365– 72. 11212130
- [10]Fisher E, Rudick RA, Simon JH, Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412– 20. 12427893
- [11]Korteweg T, Rovaris M, Neacsu V, Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler 2009; 15: 465– 71. 19091881
- [13]Wegner C, Esiri MM, Chance SA, Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960– 7. 17000961
- [14]Klaver R, Popescu V, Voorn P, Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. JNeuropatholExp Neurol 2015; 74: 453– 8. 25853695
- [15]Magliozzi R, Howell OW, Reeves C, A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477– 93. 20976767
- [16]Tedeschi G, Lavorgna L, Russo P, Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280– 5. 16043800
- [17]Fisher E, Lee JC, Nakamura K, Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255– 65. 18661561
- [18]Fisniku LK, Chard DT, Jackson JS, Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247– 54. 18570297
- [19]Roosendaal SD, Bendfeldt K, Vrenken H, Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011; 17: 1098– 106. 21586487
- [20]Dalton CM, Chard DT, Davies GR, Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101– 7. 14998914
- [21]Chard DT, Griffin CM, Rashid W, Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387– 91. 15327034
- [22]De Stefano N, Giorgio A, Battaglini M, Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868– 76. 20530323
- [23]De Stefano N, Matthews PM, Filippi M, Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157– 62. 12682324
- [24]Sailer M, Fischl B, Salat D, Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126: 1734– 44. 12805100
- [25]Shiee N, Bazin PL, Zackowski KM, Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One 2012; 7: e37049. 22615886 PMC3352847
- [26]Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 2011; 54: 278– 89. 20674750 PMC2965022
- [27]Young EA, Fowler CD, Kidd GJ, Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63: 428– 35. 18438950
- [28]Levesque I, Sled JG, Narayanan S, The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging 2005; 21: 103– 10. 15666408
- [29]van Leijsen EMC, van Uden IWM, Ghafoorian M, Nonlinear temporal dynamics of cerebral small vessel disease: The RUN DMC study. Neurology 2017; 89: 1569– 77. 28878046 PMC5634663
Cited by
Sorted by citations
Neuronal vulnerability and multilineage diversity in multiple sclerosis
Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J. H., Young, A., Steindel, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1404-z · Cited by 638 · see citing works
β-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration
Lodygin, D., Hermann, M., Schweingruber, N., Flügel-Koch, C., Watanabe, T., Schlosser, C., Merlini, A., Körner, H., Chang, H.-F., Fischer, H. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0964-2 · Cited by 140 · see citing works
Positron emission tomography in multiple sclerosis - straight to the target
Bodini, B., Tonietto, M., Airas, L., & Stankoff, B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00537-1 · Cited by 74 · see citing works
Khaw, Y. M., Tierney, A., Cunningham, C., Soto-Díaz, K., Kang, E., Steelman, A. J., & Inoue, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017213118 · Cited by 32 · see citing works
BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis
Bergner, C. G., van der Meer, F., Franz, J., Vakrakou, A., Würfel, T., Nessler, S., Schäfer, L., Nau-Gietz, C., Winkler, A., Lagumersindez-Denis, N., et al. (2025) · Brain · doi:10.1093/brain/awae293 · Cited by 16 · see citing works
- Authors
- Trapp, B. D., Vignos, M., Dudman, J., Chang, A., Fisher, E., Staugaitis, S. M., Battapady, H., Mork, S., Ontaneda, D., Jones, S. E., Fox, R. J., Chen, J., Nakamura, K., & Rudick, R. A.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Trapp, Bruce D
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 17
- Issue
- 10
- Pages
- 870-884
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC6197820
- OpenAlex
- W2888417313
- Cited by
- 146
- References
- 2
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 15 · 2023: 14 · 2022: 21 · 2021: 29 · 2020: 22 · 2019: 21 · 2018: 6
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P50NS38667, R35NS09730)
- Novartis
- National Institute of Mental Health
- Biogen
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences (CTSA KL2, KL2TR000440)
- National Multiple Sclerosis Society (RG 4348-A-7)
- Disarm Therapeutics
- Merck
- Genentech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
- Keywords
- multiple sclerosis, demyelinating lesions, myelin proteins, cortical layers, postmortem brain, spinal cord demyelination, neurological deficit, myelopathy, cingulate gyrus
- MeSH terms
- Adult, Aged, Aged, 80 and over, Autopsy, Cerebral Cortex, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Neurons, Retrospective Studies, Spinal Cord, White Matter
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review